AdvisorShares Investments LLC Acquires 5,000 Shares of GH Research PLC $GHRS

AdvisorShares Investments LLC boosted its position in shares of GH Research PLC (NASDAQ:GHRS) by 15.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,256 shares of the company’s stock after acquiring an additional 5,000 shares during the quarter. AdvisorShares Investments LLC’s holdings in GH Research were worth $466,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GHRS. XTX Topco Ltd bought a new stake in GH Research during the first quarter worth $169,000. Jefferies Financial Group Inc. bought a new stake in GH Research during the first quarter worth $8,272,000. Walleye Capital LLC bought a new stake in GH Research during the first quarter worth $584,000. Troluce Capital Advisors LLC bought a new stake in GH Research during the first quarter worth $1,716,000. Finally, RA Capital Management L.P. raised its position in GH Research by 3.9% during the first quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company’s stock worth $76,599,000 after acquiring an additional 257,959 shares in the last quarter. 56.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GHRS shares. Zacks Research lowered shares of GH Research from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research report on Wednesday, October 8th. Needham & Company LLC started coverage on shares of GH Research in a research report on Monday, October 13th. They issued a “buy” rating and a $19.00 price objective on the stock. Finally, Wall Street Zen raised shares of GH Research from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $30.38.

GH Research Stock Performance

GHRS stock opened at $12.54 on Friday. The company’s 50-day simple moving average is $13.43 and its 200 day simple moving average is $12.81. GH Research PLC has a 52 week low of $6.72 and a 52 week high of $20.50. The company has a market capitalization of $652.46 million, a PE ratio of -16.95 and a beta of 0.97.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, analysts forecast that GH Research PLC will post -0.8 EPS for the current year.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).